Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Journal of Chromatography
|
April 15, 1992
Determination of piroxicam and its major metabolites in the plasma, urine and bile of humans by high-performance liquid chromatography
P A Milligan
CPT: Pharmacometrics & Systems Pharmacology
|
July 10, 2013
The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA/EMA Modeling and Simulation Workshop
E Manolis, S Rohou, R Hemmings, et al.
European Journal of Clinical Pharmacology
|
January 1, 1993
The consequences of H2 receptor antagonist--piroxicam coadministration in patients with joint disorders
P A Milligan, P E McGill, C W Howden, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
December 6, 2013
PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST
E K Hansson, G Ma, M A Amantea, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
November 22, 2013
PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST
E K Hansson, M A Amantea, P Westwood, et al.
Clinical Pharmacology and Therapeutics
|
May 25, 2007
Model-based drug development
R L Lalonde, K G Kowalski, M M Hutmacher, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
April 13, 2016
Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation
, S F Marshall, R Burghaus, et al.
Clinical Pharmacology and Therapeutics
|
April 17, 2013
Model-based drug development: a rational approach to efficiently accelerate drug development
P A Milligan, M J Brown, B Marchant, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 31, 2015
Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development
M J Swat, S Moodie, S M Wimalaratne, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Journal of Chromatography
|
April 15, 1992
Determination of piroxicam and its major metabolites in the plasma, urine and bile of humans by high-performance liquid chromatography
P A Milligan
CPT: Pharmacometrics & Systems Pharmacology
|
July 10, 2013
The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA/EMA Modeling and Simulation Workshop
E Manolis, S Rohou, R Hemmings, et al.
European Journal of Clinical Pharmacology
|
January 1, 1993
The consequences of H2 receptor antagonist--piroxicam coadministration in patients with joint disorders
P A Milligan, P E McGill, C W Howden, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
December 6, 2013
PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST
E K Hansson, G Ma, M A Amantea, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
November 22, 2013
PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST
E K Hansson, M A Amantea, P Westwood, et al.
Clinical Pharmacology and Therapeutics
|
May 25, 2007
Model-based drug development
R L Lalonde, K G Kowalski, M M Hutmacher, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
April 13, 2016
Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation
, S F Marshall, R Burghaus, et al.
Clinical Pharmacology and Therapeutics
|
April 17, 2013
Model-based drug development: a rational approach to efficiently accelerate drug development
P A Milligan, M J Brown, B Marchant, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 31, 2015
Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development
M J Swat, S Moodie, S M Wimalaratne, et al.
Page
of 1